+91 8086000608 help@dermavue.com Open All Days · 7 Clinics
Home
All Conditions Acne Psoriasis Eczema Vitiligo Melasma Alopecia Dandruff Ringworm Rosacea Fungal Infection Seborrheic Dermatitis Acne Scars Hyperpigmentation Warts Contact Dermatitis Keloids Urticaria (Hives) Lichen Planus Folliculitis Skin Tags
Hair Transplant FUE Technique (SMART FUE) Hair Transplant Cost Beard & Mustache Transplant Eyebrow Transplantation Hair Loss Treatment Male Pattern Baldness Female Hair Loss GFC vs PRP Comparison PRP for Hair GFC PRP Platelet-Rich Fibrin (PRF) Mesotherapy Medical Treatments
Laser Hair Removal Botox Treatment Dermal Fillers HydraFacial & OxyGeneo Chemical & Enzyme Peels Laser Tattoo Removal Skin Whitening Treatment Glutathione IV Therapy MNRF Laser Toning Carbon Laser Peel Thread Lift Skin Booster Injections Non-Surgical Rhinoplasty Non-Surgical Jawline & Chin Fractional CO2 Lasers Surgical CO2 Ablation Surgical Tattoo Excision Mole, Wart & Skin Tag Removal Underarm Lightening Hand Rejuvenation Excessive Sweating Body Peel Hand and Foot Peel All Procedures →
Face Rhinoplasty (Nose Job) Non-Surgical Rhinoplasty Eye Bag Reduction Upper Eyelid Blepharoplasty Buccal Fat Removal Jawbone Contouring Eyebrow Lift Lip Reduction Dimple Creation Ear Reshaping Surgery Earlobe Repair Double Chin Reduction Body Liposuction Gynecomastia Arm Fat Correction Brachioplasty (Arm Lift) Fat Grafting Skin Scar Revision Mole Removal Xanthelasma Removal Lipoma Removal Cyst Excision
SuperHuman Program GLP-1 Injections Ozempic & Wegovy (Semaglutide) Mounjaro (Tirzepatide) Belly Fat Reduction Diet Plan & Nutrition Exercise & Fitness Plan
Gallery Shop
Coimbatore Thrissur Kochi Aluva Kottayam Thiruvalla Thiruvananthapuram Kollam
BOOK A SESSION
📞 +91 8086000608 ✉ help@dermavue.com
DOCTOR-SUPERVISED · THIRUVANANTHAPURAM · POOJAPPURA

Medical Weight Loss in Thiruvananthapuram GLP-1 Programs: Ozempic, Mounjaro & Wegovy

DermaVue's SuperHuman medical weight loss program in Thiruvananthapuram offers physician-supervised GLP-1 therapy — Mounjaro (tirzepatide), Ozempic (semaglutide), and Wegovy — for belly fat, visceral fat reduction, and metabolic health. Now at Poojappura, serving IT professionals at Technopark, families across TVM, and international patients from the Maldives. Kerala has India's highest diabetes prevalence at 25.5%. Generic semaglutide is now available in India from ₹1,290/month. All programs are physician-supervised — never unsupervised self-medication.

Check My GLP-1 Eligibility — Free

✓ No forms · Instant WhatsApp response · Doctor-supervised · From ₹1,290/month

⭐ 4.7 Stars | 1309+ Reviews ✅ Physician-Supervised 💊 All 3 GLP-1 Meds 📋 CDSCO Compliant 🏆 Kerala's #1 Rated
25.5%Kerala's diabetes rate — India's highest
32%Indians carry the thin-fat phenotype
₹1,290Generic semaglutide now available/month
THE SOUTH INDIAN THIN-FAT PARADOX

You May Look Healthy — But Your Belly Fat Tells a Different Story

Kerala ranks as India's most diabetic state, yet most patients look and feel "fine." The reason lies in the thin-fat phenotype — a genetic pattern where South Indians accumulate dangerous visceral fat at body weights that Western medicine considers normal.

Clinical Evidence — The Y-Y Paradox

In a landmark study by Dr. C.S. Yajnik and Dr. J.S. Yudkin, two physicians shared an identical BMI of 22.3 kg/m² — yet DEXA imaging revealed Yajnik had 21.2% body fat versus Yudkin's 9.1%. This "Y-Y Paradox" demonstrates that South Indians accumulate dangerous visceral fat at BMI levels considered "normal" by Western standards. Approximately 32% of India's adult population carries the thin-fat phenotype — normal BMI but metabolically equivalent to clinical obesity. Indian clinical guidelines accordingly classify overweight at BMI ≥23 (not 25) and obese at ≥25 (not 30). Kerala's 25.5% diabetes prevalence — India's highest — is the measurable consequence of this phenotype in a population where most patients look and feel "fine."

🩺 25.5%

Kerala diabetes rate — highest among all major Indian states. For educational reference only.

⚠️ BMI 23.9

In South Asians carries the same diabetes risk as BMI 30 in Europeans. Indian cutoffs differ from Western standards.

📏 85cm / 75cm

Indian waist cutoffs for men and women respectively — not the Western 102/88 cm. Physician assessment determines individual risk.

❤️ 6 years

Earlier than global average — heart attacks in Kerala strike younger. Early metabolic intervention may help reduce risk.

Check My Metabolic Risk — Free WhatsApp Assessment
5 CLINICAL TOOLS · INSTANT RESULTS · ZERO FORMS

Your Free Metabolic Health Assessment

Use our physician-designed tools to understand your metabolic risk profile. Results are instant and private — no registration required.

GLP-1 Eligibility Checker

6 quick questions to assess your candidacy. Results shown instantly.

Waist-to-Height Ratio — More Accurate Than BMI for South Indians

Two measurements, instant insight into your metabolic risk.

Metabolic Health Score — Built for Kerala's Body Types

Uses Indian BMI cutoffs, waist measurements, and clinical risk factors.

How Much Does GLP-1 Treatment Cost in Thiruvananthapuram?

Actual 2026 India pricing — generics now available.

When Will You See Results?

Realistic projections based on GLP-1 clinical trial data.

MOUNJARO · OZEMPIC · WEGOVY

GLP-1 Medications Available at DermaVue Thiruvananthapuram

Your physician determines the appropriate medication during consultation based on your health status, goals, and budget. All medications require physician prescription.

Preferred Choice

Mounjaro (Tirzepatide)

Eli Lilly — Dual GIP + GLP-1 Receptor Agonist
Weight loss
~20–22% (SURMOUNT-1 trial)
Mechanism
Dual GIP + GLP-1 (two pathways)
Approval
CDSCO: T2DM + weight management
Generics
Patent-protected until 2036–2039
₹14,000–₹27,500/month
CDSCO Weight Loss Approved

Wegovy (Semaglutide 2.4mg)

Novo Nordisk — India launch June 2025, 37% price cut Nov 2025
Weight loss
~14.9% (STEP 1, NEJM 2021)
Mechanism
High-dose GLP-1 receptor agonist
Approval
CDSCO: specifically for weight management
Note
Generic semaglutide now available from ₹1,290
₹10,850–₹16,400/month
Established

Ozempic / Generic Semaglutide

Branded (Novo Nordisk) or Generics (Natco, Zydus, Sun, Glenmark, Dr. Reddy's)
Weight loss
~12–15%
Mechanism
GLP-1 receptor agonist
Approval
CDSCO: T2DM; off-label for weight loss
Generic launch
March 20, 2026 — patent expired
Branded: ₹8,800–₹11,175 | Generic: ₹1,290–₹5,000/month
FeatureMounjaroWegovyGeneric Semaglutide
Average weight loss20–22%~14.9%~12–15%
MechanismGIP + GLP-1GLP-1 onlyGLP-1 only
CDSCO weight approvalT2DM + weight Weight onlyT2DM only
Monthly cost (India)₹14,000–27,500₹10,850–16,400₹1,290–5,000
Generic available Until 2036 Branded only March 2026
DermaVue available Preferred Available Available

Physician prescription required for all medications. Individual results vary based on medication response, dietary compliance, and metabolic profile.

PATENT EXPIRY — MARCH 20, 2026

Breaking: Generic Semaglutide Launched in India — March 20, 2026

Prices collapsed from ₹8,800 to ₹1,290/month. Medical supervision is still essential for safe, effective outcomes.

What Changed

  • Natco, Zydus, Sun Pharma, Glenmark, Dr. Reddy's generics now available
  • Price drop: ₹8,800 → ₹1,290/month (Natco/Glenmark vials)
  • Pre-filled pen versions: ₹3,600–₹5,000/month
  • Mounjaro remains patent-protected (no generics until 2036)

Why Supervision Still Matters

  • Generic vials require trained injection technique
  • Dose titration must be supervised — incorrect dosing causes severe nausea
  • Lab monitoring (thyroid, lipase, HbA1c) is required
  • CDSCO issued a safety advisory alongside generic launch
  • Side effects management requires physician access
  • 28% of India's medicines are counterfeit — verify your source
Clinical Summary — Generic Semaglutide India

The semaglutide patent expired in India on March 20, 2026, triggering immediate launches from 50+ pharmaceutical manufacturers including Natco (₹1,290), Glenmark (₹1,300–₹1,760), Dr. Reddy's Obeda (₹4,200), and Sun Pharma Noveltreat (₹3,600–₹8,000). Tirzepatide (Mounjaro) remains under Eli Lilly's patent protection until approximately 2036–2039, with no generic entry expected before then. CDSCO simultaneously issued a safety advisory urging physician supervision for all GLP-1 receptor agonist use, citing risks of unsupervised dose escalation.

Book Supervised GLP-1 Program — From ₹1,290/month
4-PILLAR PHYSICIAN-LED APPROACH

The DermaVue SuperHuman Program

Injections alone aren't enough. Studies reveal that up to 45% of weight lost during GLP-1 treatment can be lean muscle without proper supervision. Our 4-pillar program addresses this comprehensively.

1

Medical Evaluation & Body Composition

  • Comprehensive metabolic screening
  • Body composition analysis (fat vs muscle)
  • Lab panel: HbA1c, thyroid, lipase, liver, lipids
  • Trichoscopy for hair health baseline
2

Physician-Prescribed Medication Protocol

  • Medication selection: health profile, budget, target
  • Dose escalation schedule (minimise side effects)
  • CDSCO-compliant prescription documentation
  • Monthly monitoring and dose optimisation
3

Kerala Cuisine Nutrition Plan

  • Dietitian-designed for Kerala food culture
  • Puttu, appam, Kerala fish curry — NOT banned
  • High-protein adaptations of traditional meals
  • Festival/Onam/wedding navigation strategies
4

Movement & Lifestyle Integration

  • Compatible with Technopark IT schedules
  • 30-min lunch-hour effective programmes
  • AC-environment adaptations for sedentary workers
  • Sleep optimisation for cortisol/weight regulation
CANDIDATE ASSESSMENT

Am I a Candidate for GLP-1 Treatment?

Our physicians conduct comprehensive screening before prescribing any medication. Not everyone is a candidate — safety comes first.

Good Candidates

BMI ≥23 (Indian cutoffs) with any comorbidity
BMI ≥27 without comorbidity
Waist: men ≥85cm, women ≥75cm
Pre-diabetes or Type 2 diabetes
Insulin resistance
Failed multiple conventional weight loss attempts
Post-pregnancy weight retention
Technopark sedentary lifestyle with metabolic risk

Who Should NOT Use GLP-1

Personal/family history of medullary thyroid cancer
MEN2 syndrome
History of pancreatitis
Currently pregnant or planning pregnancy within 2 months
Currently breastfeeding
Severe inflammatory bowel disease
Under 18 years of age

⚕️ Medical Disclaimer: This information is for educational purposes only. Only your physician can determine GLP-1 eligibility after a complete medical assessment. DermaVue conducts comprehensive screening before any prescription.

Check My Eligibility via WhatsApp
YOUR PHYSICIANS

Meet Your Doctors at DermaVue Thiruvananthapuram

Dr. Sarath Chandran

MBBS, MD DVL — Managing Director & Clinical Lead

Dr. Sarath Chandran, MBBS, MD (DVL), is the clinical lead for the SuperHuman Medical Weight Loss & Longevity Program at DermaVue. He oversees GLP-1-based therapies, medication optimisation, and safe insulin de-escalation, working closely with dietitians to ensure patient safety and sustainable results.

"Medical weight loss is metabolic medicine — not a diet plan. We treat the biological signals, not just the symptoms."

MBBS MD DVL IADVL Registered SuperHuman Program Lead

Dr. Rejeesh Menon

MD — Co-Founder & Medical Director

Dr. Rejeesh Menon, MD (WSU, USA), is the co-founder and Medical Director of DermaVue. He provides medical oversight for all weight loss protocols, ensures international safety standards, and integrates evidence from US clinical practice into Kerala's metabolic health programmes. The SuperHuman Program's dermatology integration — monitoring for hair loss and skin laxity during rapid weight loss — reflects his vision of holistic metabolic care.

MD (USA) WSU Faculty Medical Director US Board
FROM ₹1,290/MONTH FOR MEDICATION

Transparent Pricing — No Hidden Costs

Exact pricing depends on medication choice, dose, and programme duration. WhatsApp us for a personalised quote after your initial assessment.

Essentials
₹11,000
/month (indicative)
  • Generic semaglutide included
  • Dietitian support
  • Monthly physician review
  • Basic lab monitoring
WhatsApp for Details
Recommended
SuperHuman Standard
₹15,000
/month (indicative)
  • Mounjaro or Wegovy included
  • Dietitian support
  • Fortnightly physician review
  • Full metabolic panel
  • Body composition tracking
Premium
Contact for Quote
 
  • All medications available
  • Advanced metabolic monitoring
  • Dermatology integration
  • Priority access
  • Extended support hours
Request Premium Quote

Medication alone now available from ₹1,290/month with physician supervision at DermaVue

Prices include medication, consultation, monitoring, and dietitian support. Exact pricing varies by medication choice, dose, and programme duration. EMI options available.

POOJAPPURA, THIRUVANANTHAPURAM

DermaVue Thiruvananthapuram — Accessible From Across TVM

Address
TC 42, 3003-2, Poojappura Main Rd, Kesari Nagar, Poojapura, Chengalloor, Thiruvananthapuram, Kerala 695012
Phone
+91 8330860007
WhatsApp
Message Us on WhatsApp
Email
tvm@dermavue.com
Hours
Mon–Sat: 9 AM–8 PM | Sun: 10 AM–5 PM
Consultation
₹300 Initial Consultation
Travel Times
Poojappura: 2 min Pattom: 12 min Technopark: 18 min Medical College: 8 min Neyyattinkara: 35 min Maldives: 1.5hr flight to TRV

Medical Weight Loss and GLP-1 Therapy at DermaVue

HAVE QUESTIONS?

Frequently Asked Questions — Medical Weight Loss in Thiruvananthapuram

Can I get Ozempic or Mounjaro for weight loss at DermaVue Thiruvananthapuram?
Yes. DermaVue Thiruvananthapuram prescribes Mounjaro (tirzepatide), Ozempic (semaglutide), and Wegovy under physician supervision. All prescriptions require an initial medical assessment to ensure safety and eligibility. Ozempic is CDSCO-approved for T2DM; Mounjaro is approved for both T2DM and weight management; Wegovy is approved specifically for weight management.
Is generic semaglutide available in Thiruvananthapuram? How much does it cost?
Generic semaglutide became available in India on March 20, 2026, following patent expiry. Brands including Natco, Glenmark, Dr. Reddy's Obeda, and Sun Pharma Noveltreat offer semaglutide from approximately ₹1,290–₹5,000 per month, compared to ₹8,800–₹11,175 for branded Ozempic. At DermaVue TVM, we supervise all GLP-1 programs including generic semaglutide — safe dose escalation and monitoring is essential.
What is the difference between Mounjaro and Ozempic?
Mounjaro (tirzepatide) activates two pathways — GIP and GLP-1 receptors simultaneously — while Ozempic (semaglutide) activates GLP-1 only. Clinical trials show Mounjaro produces approximately 20–22% weight loss versus ~14.9% for semaglutide 2.4mg. Mounjaro is DermaVue's preferred medication for patients requiring maximum efficacy and is fully patent-protected until approximately 2036 — no generics available.
Am I eligible for GLP-1 treatment at DermaVue Thiruvananthapuram?
Indian clinical guidelines recommend GLP-1 therapy for patients with BMI ≥27 kg/m² (or ≥25 with comorbidities such as T2DM, PCOS, or hypertension). These thresholds are lower than Western standards because South Indians develop metabolic disease at lower BMI — a condition called the thin-fat phenotype. A waist circumference above 85 cm (men) or 75 cm (women) also indicates eligibility. Our physicians conduct a full assessment before any prescription.
Why does DermaVue — a skin clinic — offer weight loss treatment?
DermaVue's SuperHuman program integrates metabolic health with dermatology because the two are inseparable. Rapid weight loss causes skin laxity, hair shedding (a documented side effect called “Ozempic face”), and changes in skin texture. DermaVue is the only clinic in Thiruvananthapuram where GLP-1 weight loss is supervised simultaneously with dermatological monitoring — preventing and treating cosmetic side effects while managing metabolic outcomes.
Kerala has the highest diabetes rate in India. Is this related to belly fat?
Yes. Kerala's 25.5% diabetes prevalence — India's highest — is directly linked to the South Indian thin-fat phenotype: normal BMI but high visceral (abdominal) fat. This visceral fat triggers insulin resistance, metabolic syndrome, and cardiovascular disease independent of total body weight. GLP-1 medications specifically target visceral fat and improve insulin sensitivity, making them particularly effective for Kerala's metabolic profile.
How long does the weight loss program take? When will I see results?
Most patients experience significant appetite reduction within the first 2–4 weeks. Visible abdominal reduction typically occurs by month 2–3. Meaningful weight loss of 5–10% of body weight is usually achieved by months 3–4. Mounjaro trials showed 20–22% weight loss over 72 weeks; Wegovy showed 14.9% over 68 weeks in the STEP 1 clinical trial. Results depend on medication choice, dietary compliance, and individual metabolic response.
Can I continue eating Kerala food during the program?
Absolutely. DermaVue's dietitian-designed meal plans are adapted to Kerala cuisine — puttu, appam, idli, fish curry, and even sadya can be modified to support weight loss goals. The focus is on portion adjustment, protein optimization, and reducing high-glycemic components rather than eliminating Kerala food culture. Festival and family gathering navigation strategies are included.
Do GLP-1 medications cause hair loss or skin changes?
“Ozempic face” — the term for facial fat loss, skin laxity, and hair shedding during rapid weight loss — is a documented concern. Hair loss is typically telogen effluvium (temporary, triggered by rapid weight change) rather than permanent. DermaVue's integration of dermatology monitoring during weight loss programs allows early detection and treatment of skin and hair changes — a service no other Thiruvananthapuram weight loss provider offers.
Is GLP-1 treatment available for Maldives patients at DermaVue TVM?
Yes. DermaVue TVM regularly treats patients from the Maldives (TRV International Airport is 25 minutes from our clinic). International patients can receive initial consultations via WhatsApp video, begin their program during their Kerala visit, and continue with remote follow-up via WhatsApp. Condensed protocols for 1–2 week visit windows are available on request.

Medical Disclaimer: This information is educational and does not constitute medical advice. Individual results vary. All treatments require medical consultation. GLP-1 medications are prescription-only and require physician supervision. Ozempic, Wegovy, and Mounjaro are registered trademarks of their respective manufacturers. DermaVue provides these medications through licensed pharmaceutical channels only. Content reviewed by Dr. Sarath Chandran, MD DVL.

Book Your SuperHuman Program Consultation in Thiruvananthapuram

₹300 Initial Consultation · Physician-Supervised · Same-Week Appointments · Generic semaglutide from ₹1,290/month

WhatsApp Eligibility Check Call +91 8330860007

📍 TC 42, 3003-2, Poojappura Main Rd, Kesari Nagar, Poojapura, Chengalloor, Thiruvananthapuram, Kerala 695012  |  📧 tvm@dermavue.com

Book Your Visit

Schedule a Consultation

Board-certified dermatologists across 7 clinics in Kerala & Tamil Nadu.

🔒 Your information is private and secure

Scroll to Top

Book a Consultation